Nektar Therapeutics Class Action Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy NKTR?
Source: PRnewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ:NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Participants are not required to pay any upfront fees or costs, as the law firm operates on a contingency fee basis, which lowers the financial barrier for investors seeking legal recourse without incurring out-of-pocket expenses.
- Case Background: The lawsuit alleges that the defendants failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, leading to overstated integrity and prospects of the trial, resulting in investor losses once the true details were disclosed.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first by ISS Securities Class Action Services in 2017, underscoring its expertise and influence in the field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 75.080
Low
102.00
Averages
123.43
High
165.00
Current: 75.080
Low
102.00
Averages
123.43
High
165.00
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nektar Therapeutics Enters Quiet Period Ahead of Rezpegaldesleukin Trial Results
- Clinical Trial Progress: Nektar Therapeutics' Rezpegaldesleukin was tested in the REZOLVE-AA study involving 92 patients with severe alopecia areata; although initial results missed statistical significance, post-exclusion of non-compliant patients showed a 30% improvement in SALT scores for both dosage groups, indicating its potential in autoimmune diseases.
- Financial Status: The company reported a net loss of $164.1 million for 2025, translating to a loss of $9.73 per share, which is an increase from the $119 million loss in 2024, while revenue dropped from $98.4 million to $55.2 million, highlighting challenges in revenue generation and profitability.
- Safety Advantages: Rezpegaldesleukin demonstrated a favorable safety profile in clinical trials, with no increased risk of serious adverse events, and the most common treatment-emergent adverse effects were mild to moderate injection site reactions, underscoring its potential as a first-in-class biologic for alopecia areata.
- Market Outlook: With approximately 700,000 people in the U.S. affected by alopecia areata, Nektar's Rezpegaldesleukin, with its differentiated safety and efficacy, could emerge as a new treatment option in a competitive market, making upcoming clinical data releases crucial for investors to monitor.
See More
Nektar Therapeutics Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ:NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Participants are not required to pay any upfront fees or costs, as the law firm operates on a contingency fee basis, which lowers the financial barrier for investors seeking legal recourse without incurring out-of-pocket expenses.
- Case Background: The lawsuit alleges that the defendants failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, leading to overstated integrity and prospects of the trial, resulting in investor losses once the true details were disclosed.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first by ISS Securities Class Action Services in 2017, underscoring its expertise and influence in the field.
See More
Class Action Filed Against Nektar for Misleading Statements
- Class Action Initiation: Bragar Eagel & Squire has filed a class action lawsuit against Nektar Therapeutics in the Northern District of California on behalf of investors who purchased Nektar securities between February 26, 2025, and December 15, 2025, with a deadline of May 5, 2026, for investors to apply as lead plaintiffs.
- Allegation Details: The lawsuit alleges that Nektar failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, which likely overstated the trial's integrity and prospects, rendering the company's public statements materially false and misleading during the relevant period.
- Significant Stock Drop: Following the December 16, 2025, announcement that the REZOLVE-AA trial did not achieve statistical significance, Nektar's stock price plummeted by $4.14, or 7.77%, closing at $49.16 per share, indicating a severe loss of investor confidence in the company's future.
- Investor Rights Advocacy: Bragar Eagel & Squire encourages all investors who suffered losses during the class period to reach out for more information on their claims, demonstrating the firm's commitment to protecting investor rights and interests.
See More
Reminder of Class Action for Nektar Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will not incur any upfront costs, as attorney fees will be collected through a contingency fee arrangement, allowing them to seek compensation without financial burden.
- Case Background: The lawsuit alleges that defendants failed to adhere to applicable instructions and standards in the REZOLVE-AA trial, raising concerns about the trial's integrity and leading to investor losses when the true details emerged.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in the field.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Nektar Therapeutics in the Northern District of California on behalf of investors who purchased securities between February 26, 2025, and December 15, 2025, seeking damages for violations of federal securities laws, highlighting serious investor concerns regarding the company's compliance.
- Trial Results Disappoint: On December 16, 2025, Nektar disclosed that its REZOLVE-AA trial failed to achieve statistical significance, resulting in a 7.77% drop in stock price, which reflects potential issues in the company's drug development process and may undermine future investor confidence.
- Recruitment Controversy: The lawsuit alleges that Nektar's enrollment in the REZOLVE-AA trial did not adhere to applicable standards, likely impacting trial results negatively, which not only damages the company's reputation but also raises questions about the compliance of future clinical trials.
- Potential Legal Consequences: Investors must apply by May 5, 2026, to be appointed as Lead Plaintiff in the class action, indicating that this case could lead to broader legal and financial repercussions, further affecting Nektar's market performance and shareholder trust.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and December 15, 2025, with a deadline for participation set for May 5, 2026.
- False Statements Allegation: The complaint alleges that Nektar failed to adhere to protocol standards in its REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial results, while the company overstated the integrity of the trial in its public statements, misleading investors.
- Market Reaction: As the market became aware of the truth regarding Nektar's practices, investors suffered losses, highlighting the direct impact of the company's misconduct on its stock price and investor confidence, potentially leading to a decline in share value.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations, encouraging affected shareholders to reach out to discuss their rights, demonstrating the firm's commitment to protecting investor interests while providing legal support for potential class action participation.
See More
Nektar Therapeutics Enters Quiet Period Ahead of Rezpegaldesleukin Trial Results
- Clinical Trial Progress: Nektar Therapeutics' Rezpegaldesleukin was tested in the REZOLVE-AA study involving 92 patients with severe alopecia areata; although initial results missed statistical significance, post-exclusion of non-compliant patients showed a 30% improvement in SALT scores for both dosage groups, indicating its potential in autoimmune diseases.
- Financial Status: The company reported a net loss of $164.1 million for 2025, translating to a loss of $9.73 per share, which is an increase from the $119 million loss in 2024, while revenue dropped from $98.4 million to $55.2 million, highlighting challenges in revenue generation and profitability.
- Safety Advantages: Rezpegaldesleukin demonstrated a favorable safety profile in clinical trials, with no increased risk of serious adverse events, and the most common treatment-emergent adverse effects were mild to moderate injection site reactions, underscoring its potential as a first-in-class biologic for alopecia areata.
- Market Outlook: With approximately 700,000 people in the U.S. affected by alopecia areata, Nektar's Rezpegaldesleukin, with its differentiated safety and efficacy, could emerge as a new treatment option in a competitive market, making upcoming clinical data releases crucial for investors to monitor.
See More
Nektar Therapeutics Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ:NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Participants are not required to pay any upfront fees or costs, as the law firm operates on a contingency fee basis, which lowers the financial barrier for investors seeking legal recourse without incurring out-of-pocket expenses.
- Case Background: The lawsuit alleges that the defendants failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, leading to overstated integrity and prospects of the trial, resulting in investor losses once the true details were disclosed.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first by ISS Securities Class Action Services in 2017, underscoring its expertise and influence in the field.
See More
Class Action Filed Against Nektar for Misleading Statements
- Class Action Initiation: Bragar Eagel & Squire has filed a class action lawsuit against Nektar Therapeutics in the Northern District of California on behalf of investors who purchased Nektar securities between February 26, 2025, and December 15, 2025, with a deadline of May 5, 2026, for investors to apply as lead plaintiffs.
- Allegation Details: The lawsuit alleges that Nektar failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, which likely overstated the trial's integrity and prospects, rendering the company's public statements materially false and misleading during the relevant period.
- Significant Stock Drop: Following the December 16, 2025, announcement that the REZOLVE-AA trial did not achieve statistical significance, Nektar's stock price plummeted by $4.14, or 7.77%, closing at $49.16 per share, indicating a severe loss of investor confidence in the company's future.
- Investor Rights Advocacy: Bragar Eagel & Squire encourages all investors who suffered losses during the class period to reach out for more information on their claims, demonstrating the firm's commitment to protecting investor rights and interests.
See More
Reminder of Class Action for Nektar Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will not incur any upfront costs, as attorney fees will be collected through a contingency fee arrangement, allowing them to seek compensation without financial burden.
- Case Background: The lawsuit alleges that defendants failed to adhere to applicable instructions and standards in the REZOLVE-AA trial, raising concerns about the trial's integrity and leading to investor losses when the true details emerged.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in the field.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Nektar Therapeutics in the Northern District of California on behalf of investors who purchased securities between February 26, 2025, and December 15, 2025, seeking damages for violations of federal securities laws, highlighting serious investor concerns regarding the company's compliance.
- Trial Results Disappoint: On December 16, 2025, Nektar disclosed that its REZOLVE-AA trial failed to achieve statistical significance, resulting in a 7.77% drop in stock price, which reflects potential issues in the company's drug development process and may undermine future investor confidence.
- Recruitment Controversy: The lawsuit alleges that Nektar's enrollment in the REZOLVE-AA trial did not adhere to applicable standards, likely impacting trial results negatively, which not only damages the company's reputation but also raises questions about the compliance of future clinical trials.
- Potential Legal Consequences: Investors must apply by May 5, 2026, to be appointed as Lead Plaintiff in the class action, indicating that this case could lead to broader legal and financial repercussions, further affecting Nektar's market performance and shareholder trust.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and December 15, 2025, with a deadline for participation set for May 5, 2026.
- False Statements Allegation: The complaint alleges that Nektar failed to adhere to protocol standards in its REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial results, while the company overstated the integrity of the trial in its public statements, misleading investors.
- Market Reaction: As the market became aware of the truth regarding Nektar's practices, investors suffered losses, highlighting the direct impact of the company's misconduct on its stock price and investor confidence, potentially leading to a decline in share value.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations, encouraging affected shareholders to reach out to discuss their rights, demonstrating the firm's commitment to protecting investor interests while providing legal support for potential class action participation.
See More
